Hyperpituitarism (Prolactin Secreting Pituitary Dysfunction) — VA Rating (DC 7916)
Diagnostic Code 7916 · 38 CFR §4.119
What Is It?
Hyperpituitarism under DC 7916 refers specifically to prolactin secreting pituitary dysfunction, usually a prolactinoma, which is a benign pituitary tumor that pours out prolactin. The excess hormone suppresses the reproductive axis, so men often present with low testosterone, low libido, erectile dysfunction, and fatigue, and women with irregular or absent periods, infertility, and milk production unrelated to childbirth. Larger tumors add mass effect: headaches, pressure on the optic chiasm that erodes the outer edges of both visual fields, and loss of the other pituitary hormones. Veterans usually reach the diagnosis sideways, after a workup for headaches, for infertility, or for a testosterone level that came back low on a routine panel, and the symptoms are often carried for years as depression or as ordinary fatigue. Under 38 CFR §4.119, DC 7916 carries no percentage tiers of its own. The instruction is to evaluate as a malignant or benign neoplasm, as appropriate. Because prolactinomas are almost always benign, most claims route to DC 7915, which in turn says to rate as residuals of endocrine dysfunction. The evaluation therefore comes from the hormone loss, the vision, the headaches, and the effects of treatment, each rated under its own code and combined under 38 CFR §4.25.
Rating Criteria
| Rating | Criteria |
|---|---|
| See pathways | DC 7916 (hyperpituitarism, prolactin secreting pituitary dysfunction) assigns no percentage of its own under 38 CFR §4.119. The instruction is to evaluate as malignant or benign neoplasm, as appropriate. Malignant tumors are evaluated under DC 7914 at 100 percent, continuing beyond the cessation of any surgical, X-ray, antineoplastic chemotherapy or other therapeutic procedure, with the rating determined by mandatory VA examination six months after treatment is discontinued and residuals rated thereafter. Benign tumors — which is nearly all prolactinomas — are evaluated under DC 7915, which routes again to residuals of endocrine dysfunction. Those residuals include the hormone deficiencies a large tumor causes, visual field loss under the eye codes, headaches, erectile dysfunction under DC 7522, infertility, and bone loss, each evaluated under its own code and combined under 38 CFR §4.25. |
Evidence Needed
Serial prolactin levels showing the pattern before and during treatment are the starting point, along with the pituitary MRI with and without contrast that names the lesion and gives its size, since a microadenoma and a macroadenoma behave differently. Add the rest of the pituitary axis: testosterone with LH and FSH, estradiol in women, IGF-1, a morning cortisol with ACTH, and TSH with free T4, because a large tumor can knock out more than prolactin. Formal visual field testing by perimetry is essential if the tumor touches or approaches the optic chiasm. Then the treatment record: cabergoline or bromocriptine doses with side effects, any transsphenoidal surgery operative note and pathology, radiation records, fertility evaluations, and a bone density scan if the hormone loss ran untreated for years.
C&P Exam Tips
Bring the MRI report with the measurement of the tumor and your most recent prolactin level. Describe the reproductive symptoms plainly, because they are routinely underreported and they carry evaluation weight: erectile dysfunction, loss of libido, infertility, absent periods, breast discharge. Describe headaches by frequency, duration, and what they stop you from doing. If you have been bumping into door frames, missing objects to the side, or having trouble with peripheral vision while driving, say so and ask for formal visual field testing rather than a bedside check. Report medication side effects honestly, including nausea, dizziness, mood change, and any compulsive behavior on a dopamine agonist. Ask whether separate eye and mental health examinations are being scheduled.
How to File
File VA Form 21-526EZ listing hyperpituitarism under DC 7916. Include pituitary MRI, hormone levels, and treatment records. Because DC 7916 is rated based on its neoplastic and hormonal effects, file separate claims for sexual dysfunction, vision problems, osteoporosis, depression, and any other residuals under their appropriate diagnostic codes. If the tumor developed after a service-connected head injury, include that documentation.
Common Mistakes
The first mistake is claiming the tumor and nothing else. DC 7916 has no percentage, so a claim naming only the prolactinoma routes to DC 7915 and then to residuals that were never described. The second is leaving out the reproductive consequences because they are uncomfortable to discuss. Erectile dysfunction and infertility are evaluated conditions, and they can also support special monthly compensation for loss of use of a creative organ, which nobody considers if it is never raised. The third is accepting a bedside vision check instead of formal perimetry when the tumor is anywhere near the optic chiasm. The fourth is assuming that a medication which normalized the prolactin level means there is nothing left to rate, when the fatigue, the hormone loss, and the side effects continue.
Frequently Asked Questions
Why does DC 7916 have no percentage?
Because the code is a routing instruction. DC 7916 says to evaluate as a malignant or benign neoplasm, as appropriate, so the percentage comes from DC 7914 for a malignant tumor or DC 7915 for a benign one. DC 7915 then says to rate as residuals of endocrine dysfunction, which moves the evaluation onto the hormone deficiencies, the vision, and the effects of treatment. Two steps of routing is unusual, and it is a large part of why these claims come back decided with no evaluation attached.
Which neoplasm code does my case route to?
Almost always the benign path. Prolactinomas are benign tumors, so DC 7916 sends the claim to DC 7915 and from there to residuals of endocrine dysfunction. The malignant path under DC 7914, which provides 100 percent continuing beyond the cessation of surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure, applies only where the pathology or the treating oncologist documents malignancy. If antineoplastic therapy was used, put that fact in front of the rater plainly, because it changes the route.
Can low testosterone and erectile dysfunction be rated separately?
Yes. Hormone deficiency, erectile dysfunction, infertility, and any other consequence the tumor caused are separate impairments evaluated under their own codes, and separate evaluations are combined under 38 CFR §4.25 rather than added. Erectile dysfunction and infertility may also support special monthly compensation for loss of use of a creative organ, which is decided separately from the percentage evaluation. None of this happens on its own, so list each consequence by name in the claim and again at the examination.
Medication controls my prolactin level. Does that hurt the claim?
No, and the record should show why. A dopamine agonist can bring the prolactin level down while leaving fatigue, headaches, low testosterone, mood changes, and medication side effects in place, and the medication itself is a permanent requirement rather than a cure. Report symptoms as they are while on treatment, note every dose change and the reason for it, and record side effects such as nausea, dizziness, and compulsive behavior. A normal lab value alongside an unchanged daily experience is worth explaining in your own words.
How is vision loss from a pituitary tumor handled?
Vision loss from a pituitary tumor is classically the loss of the outer halves of both visual fields, and it comes on slowly enough that people adapt without noticing. It is evaluated under the eye codes for impairment of visual fields, or under the diplopia criteria where double vision is present, separately from the endocrine evaluation. The evidence that supports it is formal perimetry with a printed field chart. Ask for the test by name, keep the printouts, and repeat it if the tumor grows or the surgery is revised.